Smith+Nephew embarks on the OXINIUM™ Technology Tour of Change; a mobile learning exhibit to showcase the best performing bearing for total hip arthroplasty

Rhea-AI Summary

Smith+Nephew (LSE: SN, NYSE: SNN) has launched the OXINIUM Technology Tour of Change, a 550-square-foot mobile exhibit covering 20 U.S. cities over 12 weeks. This initiative showcases OXINIUM Technology, recognized for its low revision risk in total hip arthroplasty, with over two million clinical cases. The exhibit aims to educate healthcare professionals on the unique manufacturing of OXINIUM, emphasizing its durability, wear resistance, and absence of harmful nickel, cobalt, and chromium. The tour also highlights OXINIUM's integration with Smith+Nephew's Real Intelligence platform.

Positive

• Launch of the OXINIUM Technology Tour enhances brand visibility across 20 U.S. cities.
• OXINIUM Technology showcases low revision rates and proven performance in hip and knee replacements.
• Innovative manufacturing process reduces harmful components, complying with new EU-MDR standards.

Negative

• None.

LONDON, March 15, 2022 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces it has kicked-off the OXINIUM Technology Tour of Change mobile exhibit. OXINIUM (Oxidized Zirconium) Technology has established itself as the best performing bearing with the lowest risk of revision in total hip arthroplasty (THA) at 9-17 years^1-4, with strong clinical performance in knees.^5,6

The Tour of Change is a 550 square foot mobile exhibit that will visit leading Orthopaedic centers in approximately 20 U.S. cities over 12 weeks. It is designed to provide HCPs with an opportunity to learn how OXINIUM Technology is a truly differentiated implant material, how an implant is made, and how it has been applied clinically during the last 20 years in over two million cases, delivering proven clinical performance in hip and knee replacements.^1-6 

Through a unique manufacturing process, the OXINIUM alloy becomes a ceramicised metal - a true material transformation - rather than an applied coating.⁷ It is this material transformation that provides OXINIUM Oxidized Zirconium with its ground-breaking performance benefits which include:

• Unrivalled Material Science: The durability of metal, the wear resistance of ceramic and corrosion resistance better than both.^7-16
• Proven Clinical Performance: The lowest risk of revision in primary hips in four national and regional registries, as well as A/A ratings for OXINIUM knees from the Orthopaedic Device Evaluation Panel (ODEP)^1-5
• Differentiated Composition: Virtually no nickel, cobalt and chromium, with a lower pro-inflammatory profile in vitro than CoCr^*,16. As such, OXINIUM implants will not be labelled as CMR (carcinogenic, mutagenic, reprotoxic) under the new EU-MDR cobalt label requirements.

"As the number of cases increase and the age of patients broadens in hip and knee arthroplasty,^17-19 the demand for a high-performance bearing surface that can deliver proven clinical performance grows,^1-6" stated Randy Kilburn, Executive Vice President & General Manager, Orthopaedic Reconstruction, Robotics and Digital for Smith+Nephew. "Corrosion, wear and aseptic loosening can all impact short-term clinical outcomes, implant survivorship, and quality of life for the patient,^20,21 so surgeons need an implant material that can address these concerns through material science.^7-16

There will also be an opportunity on the Tour of Change for HCPs to learn more about how OXINIUM Technology can be used with Smith+Nephew's Real Intelligence portfolio to combine material, design and placement. This includes the CORI^™ Surgical System – a next generation, handheld robotics-assisted platform.

To learn more information about where you can visit the Tour of Change and how OXINIUM Oxidized Zirconium delivers the durability of metal, the wear resistance of ceramic, and corrosion resistance better than both^7-16, please go to www.oxinium.com/tourofchange.

References

1. Davis ET, Pagkalos J, Kopjar B. Bearing surface and survival of cementless and hybrid total hip arthroplasty in the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man. JBJS. 2020;5(2):pe0075.
2. Peters RM, Van Steenbergen LN, Stevens M, et al. The effect of bearing type on the outcome of total hip arthroplasty. Acta Orthopaedica. 2018; 89(2):163-169.
3. Atrey A, Ancarani C, Fitch D, Bordini B. Impact of bearing couple on long-term component survivorship for primary cementless total hip replacement in a large arthroplasty registry. Poster presented at: Canadian Orthopedic Association; June 20–23, 2018; Victoria, British Columbia, Canada.
4. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2021 Annual Report.
5. ODEP Product Rating "OXINIUM". Available at: https://www.odep.org.uk/products.aspx. Accessed March 1st, 2022.
6. Innocenti M, Matassi F, Carulli C, Nistri L, Civinini C. Oxidized zirconium femoral component for TKA: A follow-up note of a previous report at a minimum of 10 years. The Knee. 2014;21:858–861.
7. Hunter G, Dickinson J, Herb B, et al. Creation of oxidized zirconium orthopaedic implants. Journal of ASTM International. 2005;2:1-14.
8. Long M, Riester L, Hunter G. Nano-hardness Measurements of Oxidized Zr-2.5Nb and Various Orthopaedic Materials. Abstract presented at: 24th Annual Meeting of the Society for Biomaterials. April 22-26, 1998, San Diego, California.
9. Parikh A, Hill P, Hines G, Pawar V. Wear of conventional and highly crosslinked polyethylene liners during simulated fast walking/jogging. Poster presented at: 55th Annual Meeting of the Orthopaedic Research Society, 2009. Poster no. 2340.
10. Parikh A, Hill P, Pawar V, Sprague J. Long-term Simulator Wear Performance of an Advanced Bearing Technology for THA. Poster presented at: 2013 Annual Meeting of the Orthopaedic Research Society. Poster no. 1028.
11. Papannagari R, Hines G, Sprague J, Morrison M. Long-term wear performance of an advanced bearing technology for TKA. Poster presented at: 2011 Annual Meeting of the Orthopaedic Research Society. Poster no. 1141.
12. Smith+Nephew 2010. OR-10-155.
13. Aldinger P, Williams T, Woodard E. Accelerated Fretting Corrosion Testing of Zirconia Toughened Alumina Composite Ceramic and a New Composition of Ceramicised Metal Femoral Heads. Poster presented at: 2017 Annual Meeting of the Orthopaedic Research Society. Poster no. 1037.
14. Smith+Nephew 2016. OR-16-127.
15. 2005 ASM International Engineering Materials Achievement Award.
16. Dalal A, Pawar V, McAllister K, Weaver C, Hallab NJ. Orthopedic implant cobalt-alloy particles produce greater toxicity and inflammatory cytokines than titanium alloy and zirconium alloy-based particles in vitro, in human osteoblasts, fibroblasts, and macrophages. J Biomed Mater Res Part A. 2012;100A:2147-2158.
17. Klug A, Gramlich Y, Rudert M, et al. The projected volume of primary and revision total knee arthroplasty will place an immense burden on future health care systems over the next 30 years. Knee Surgery, Sports Traumatology, Arthroscopy. 2020;15:1-12.
18. Sloan M, Premkumar A, Sheth NP. Projected Volume of Primary Total Joint Arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am. 2018;100:1455-1460.
19. Ackerman IN, Bohensky MA, Zomer E, et al. The projected burden of primary total knee and hip replacement for osteoarthritis in Australia to the year 2030. BMC Musculoskeletal Disorders. 2019;23(1):90.
20. Fernandez-Fernandez R, Cruz-Pardos A, Garcia-Rey E. Revision Total Hip Arthroplasty: Epidemiology and Causes. In: Rodríguez-Merchán E. Revision Total Joint Arthoplasty. Springer, 2020.
21. Lewis PL, Robertsson O, Graves SE, et al. Variation and trends in reasons for knee replacement revision: a multi-registry study of revision burden. Acta Orthopaedica. 2020. 2021:92(2):182-8.

* ASTM International Standard Specification for Wrought Zirconium-2.5 Niobium Alloy for Surgical Implant Applications (UNS R60901) Designation: F 2384 – 10.

About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

™Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

View original content to download multimedia:https://www.prnewswire.com/news-releases/smithnephew-embarks-on-the-oxinium-technology-tour-of-change-a-mobile-learning-exhibit-to-showcase-the-best-performing-bearing-for-total-hip-arthroplasty-301502695.html

SOURCE Smith & Nephew plc

FAQ

What is the purpose of the OXINIUM Technology Tour of Change by Smith+Nephew?

The OXINIUM Technology Tour aims to educate healthcare professionals about the benefits of OXINIUM Technology in hip and knee replacements.

How many cities will the OXINIUM Technology Tour visit?

The OXINIUM Technology Tour will visit approximately 20 U.S. cities over a span of 12 weeks.

What are the key benefits of OXINIUM Technology highlighted in the tour?

OXINIUM Technology is known for its low revision risk in total hip arthroplasty and its durability, wear resistance, and lower pro-inflammatory profile.

What is unique about OXINIUM's manufacturing process?

OXINIUM undergoes a unique transformation that turns it into a ceramicised metal, providing superior performance without harmful coatings.

When did Smith+Nephew announce the OXINIUM Technology Tour?

Smith+Nephew announced the OXINIUM Technology Tour on March 15, 2022.